You just read:

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

News provided by

Palatin Technologies, Inc.

Mar 26, 2018, 08:00 ET